2019年度発表論文等一覧

原著論文－英文

1. Kitazawa M, Hatta T, Sasaki Y, Fukui K, Ogawa K, Fukuda E, Goshima N, Okita N, Yamada Y, Nakagama H, Natsume T, Horimoto K.
   Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer. Cancer Sci 111:658-666, 2019. (IF: 6.716)
2. Suzuki K, Naito T, Tanaka H, Yamada Y, Itoh K, Kawakami J.
   A Reversed-Phase Mode LC-MS/MS Method Using a Polysaccharide Chiral Selector for Simultaneous Quantitation of Each Enantiomer of Tramadol and its Metabolites in Human Plasma and Evaluation of CYP-Mediated Stereoselective Demethylation. Ther Drug Monitor 42: 503-511, 2019. (IF: 2.073)
3. Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N, Nagashima K, Ito Y, Itami J.
   Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus 16: 402-407, 2019. (IF: 4.230)
4. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M.
   Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4:501-510, 2019. (IF: 14.781)
5. Matsuyama T, Ishikawa T, Takahashi N, Yamada Y, Yasuno M, Kawano T, Uetake H, Goel A.
   Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer. Mol Cancer 18: 19, 2019. (IF: 16.959)
6. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.
   Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
   Cancer Sci. 110(4), Apr, 2019.
7. Kamiya A, Hayama Y, Kato S, Shimomura A, Shimomura T, Irie K, Kaneko R, Yanagawa Y, Kobayashi K, Ochiya T.
   Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression.
   Nat Neurosci. 22(8), Aug, 2019.
8. Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K.
   Brain metastasis-related microRNAs in patients with advanced breast cancer.
   PLoS One. 14(19), Oct, 2019.
9. Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Kato K, Shimizu C, Ochiya T, Tamura K.
   Serum microRNA- based prediction of responsiveness to eribulin in metastatic breast cancer.
   PLoS One. 14(9), Sep, 2019.
10. Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.
    Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Med Oncol. 36(7), May, 2019.
11. Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.
    The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.
    Intern Med. 58(10), May, 2019.
12. Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.
    Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
    Breast Cancer. 26(4), Jul, 2019.
13. Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N.
    Improved survival among patients enrolled in oncology phase 1 trials in recent decades.
    Cancer Chemother Pharmacol. 85(2), Feb, 2020.
14. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K.
    Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation.
    Case Rep Oncol Med. , Mar, 2020.
15. Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T.
    Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs.
    BMJ Support Palliat Care. , Jan, 2020.
16. Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N.
    First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
    Cancer Sci. 111(2), Feb, 2020.

原著論文－和文

1. 下村昭彦.
   Detecting Early Breast Cancer by Serum MicroRNA.
   Gan To Kagaku Ryoho. 2019 Dec;46(12):1837-1840.

口頭・ポスター発表－国際学会・研究会

1. Shimomura A.
   A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer. (JCOG1607 HERB TEA study).
   American Society of Clinical Oncology Annual Meeting. Chicago, USA, Jun, 2019.

口頭・ポスター発表－国内学会・研究会会

1. 下村昭彦.
   がん治療における患者力向上のための医療者の役割.
   第34回日本がん看護学会学術集会. 東京, 2, 2020.